©2014 UIC Division of Cardiology, University of Illinois at Chicago  

840 S. Wood St., MC 715, Chicago IL 60612 | Privacy Notice | Contact Webmaster |

DIVISION OF CARDIOLOGY
HOME ABOUT US DIRECTORY CLINICAL PROGRAMS RESEARCH EDUCATION GIVING

George T. Kondos, MD., Division Chief

Research

ENROLL IN A CLINICAL TRIAL

Contact the Clinical Trials Office 312-996-0572 or 312-996-1247.



The division of cardiology is involved in a variety of clinical trials, with the aim to define the highest clinical, educational, and research standards in our profession.


Research in the division of cardiology focuses on diagnostic and therapeutic strategies through extensive collaborations and use of core facilities. Clinical trials influence the practice of medicine and improve the quality of care to our patients. We put this commitment into practice every day to foster continuous quality and improve outcomes.



Current Clinical Trials:


CHART:

Congestive Heart Failure Adherence Redesign Trial


PI: Thomas Stamos, M.D (UIC)

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #:

Sponsor: NIH

Study Status: Closed for enrollment



COMMANDER-HF (RIVAROXHFA3001):

PI: Thomas Stamos, M.D (UIC)

Purpose: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Chronic Heart Failure and Significant Coronary Artery Disease Following a Hospitalization for Exacerbation of Heart Failure

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #:  

Sponsor: Janssen Research and Development, LLC

Study Status: open for enrollment



COSMIC-HF:


Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure


PI: Thomas Stamos, M.D (UIC)

Purpose: A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and Left Ventricular Systolic Dysfunction (AMG 423 20ll0l5l)

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #:

Study Status: open for enrollment



The DAPT Study:

Gauging Responsiveness with A VerifyNow assay- Impact on Thrombosis and Safety


PI: Mladen Vidovich, M.D

Purpose: A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 month of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #:

Study Status: closed for enrollment



FAME3 Trial:

Fractional Flow Reserve Versus Angiography for Multivessel Evaluation


PI: Mladen Vidovich, M.D

Purpose:

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #:

Study Status: open for enrollment




ODYSSEY:


PI: Mladen Vidovich, M.D

Purpose: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #:

Sponsor: Sanofi-Aventis

Study Status: Closed for enrollment




PARAGON-HF:


PI: Thomas Stamos, M.D

Purpose: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction (CLCZ696D2301)

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #: Pending

Sponsor: NOVARTIS

Study Status: Not yet open for enrollment




PARAGON-HF:

PI: Thomas Stamos, M.D

Purpose: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction (CLCZ696D2301)

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #: Pending

Sponsor: NOVARTIS

Study Status: Not yet open for enrollment

ODYSSEY:

PI: Mladen Vidovich, M.D

Purpose: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #:

Sponsor: Sanofi-Aventis

Study Status: Closed for enrollment



ODYSSEY:

PI: Mladen Vidovich, M.D

Purpose: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #:

Sponsor: Sanofi-Aventis

Study Status: Closed for enrollment



ODYSSEY:

PI: Mladen Vidovich, M.D

Purpose: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #:

Sponsor: Sanofi-Aventis

Study Status: Closed for enrollment




PARAGON-HF:

PI: Thomas Stamos, M.D

Purpose: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction (CLCZ696D2301)

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #: Pending

Sponsor: NOVARTIS

Study Status: Not yet open for enrollment


PARAGON-HF:

PI: Thomas Stamos, M.D

Purpose: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction (CLCZ696D2301)

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #: Pending

Sponsor: NOVARTIS

Study Status: Not yet open for enrollment


PARAGON-HF:

PI: Thomas Stamos, M.D

Purpose: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction (CLCZ696D2301)

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #: Pending

Sponsor: NOVARTIS

Study Status: Not yet open for enrollment

 



PARAGON-HF:

PI: Thomas Stamos, M.D

Purpose: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction (CLCZ696D2301)

Study Contact: Felipe E. Mendez, BS, CCRC

IRB #: Pending

Sponsor: NOVARTIS

Study Status: Not yet open for enrollment